Why patellofemoral OA is not the same as knee OA elsewhere

Sitting through a film, walking down a flight of stairs, or holding a deep squat — these are the moments that patellofemoral osteoarthritis (PFOA) makes itself felt. The pain sits at the front of the knee, behind or around the kneecap, and it tends to build with sustained bent-knee positions in a way that straightforward knee arthritis typically does not.

The reason lies in anatomy. The kneecap (patella) glides up and down within a groove at the front of the thigh bone (the trochlea), forming its own joint — the patellofemoral compartment. This is structurally and mechanically separate from the medial and lateral compartments where the thigh bone meets the shin bone (tibiofemoral joints). When cartilage in the patellofemoral compartment wears down, the result is PFOA — a condition that can exist entirely on its own, or sit alongside tibiofemoral disease, where it may still require different management priorities.

The distinction matters in practice. The muscles that stabilise patellar tracking, the imaging views needed to assess it, and the criteria used to select patients for injection therapy all differ from those applied to tibiofemoral OA. Identifying which compartment is involved is the first practical step towards an appropriate management plan.

How PFOA is assessed — examination and imaging

Assessment begins in the consulting room, with a targeted physical examination that differs materially from a standard knee OA review. Rather than focusing on joint-line tenderness or medial and lateral stability — the hallmarks of tibiofemoral OA examination — the PFOA assessment centres on how the kneecap tracks during movement. The J-sign (an S-shaped deviation of the patella as the knee extends) and Clarke's or grind test give the clinician information about patellar mechanics and cartilage irritation. Patellar apprehension testing assesses whether the kneecap feels unstable under lateral pressure. Hip abductor and quadriceps (particularly VMO) strength are also evaluated, since weakness in these muscle groups is a recognised driver of patellar maltracking — a detail that directly shapes the management plan.

Imaging

A standard weight-bearing AP knee X-ray — taken with the patient standing and the beam directed at the front of the joint — is the routine starting point for tibiofemoral OA grading, but it does not show the back surface of the kneecap or the retropatellar joint space. Dedicated patellar views (Merchant, sunrise, or skyline projections) are therefore required to assess patellar tilt, lateral subluxation, and retropatellar joint-space narrowing.

Where further detail is needed, MRI and CT provide information that plain films cannot: trochlear morphology, patellar tracking dynamics, and the tibial tuberosity–trochlear groove (TT-TG) distance — a measurement used to quantify patellar malalignment that has no direct equivalent in tibiofemoral OA assessment. It is worth noting that the degree of cartilage loss visible on imaging does not always correspond to symptom severity; imaging findings are one input in the clinical picture, not a verdict in themselves.

For a small proportion of patients — typically those where imaging findings and symptoms remain difficult to reconcile after thorough investigation — dynamic needle arthroscopy may be used in specialist centres. This minimally invasive outpatient procedure allows direct, real-time visualisation of the patellofemoral cartilage and joint mechanics, and can clarify questions that static imaging is unable to settle.

First-line management: what to try before injections

Before any injection is considered, a structured rehabilitation programme is the established starting point — and for most patients, it is enough to produce meaningful improvement.

NICE guideline NG226 (2022) is explicit on this: non-pharmacological and pharmacological management should be fully explored before progressing to injection therapy or surgical referral. In PFOA, that principle takes a specific practical form. Strengthening the VMO — the medial portion of the quadriceps that provides the kneecap's primary medial pull — and the hip abductors addresses the biomechanical cause of patellar maltracking directly. As the assessment section noted, weakness in these muscle groups is a recognised driver of the problem; a physiotherapy programme that targets both is therefore the primary intervention, not a preliminary hurdle before more active treatment.

Simple analgesia runs in parallel: paracetamol and topical NSAIDs as first choices, with oral NSAIDs considered where appropriate and individually tolerated. Patellofemoral taping, foot orthotics, and short-term load modification — limiting deep squats or prolonged stair descent during acute flares — are practical adjuncts that reduce symptom burden while rehabilitation gains accumulate.

Most patients who engage consistently with this approach report significant reduction in anterior knee pain. For those whose symptoms remain persistent despite genuine effort over an adequate period, injection therapy is the appropriate next step.

When injection therapy becomes appropriate

Three criteria, taken together, form the basis of a decision to move from conservative management to injection therapy in PFOA.

The first is that structured rehabilitation and simple analgesia have been given a genuine trial — not a handful of sessions, but consistent physiotherapy long enough for VMO and hip abductor strengthening to take meaningful effect. If symptoms remain disabling after that, injection therapy becomes a reasonable next step.

The second is imaging-confirmed cartilage status. As the assessment section covers, the relevant imaging in PFOA comes from patellar-specific views or MRI rather than a standard weight-bearing X-ray; what matters for injection candidacy is that those images show mild-to-moderate, sub-total cartilage wear rather than bone-on-bone loss. At end-stage disease, injectable agents including hyaluronic acid have substantially reduced efficacy — a finding supported by multiple systematic reviews, including the 2015 network meta-analysis by Bannuru et al. in the Annals of Internal Medicine — and the clinical conversation should shift towards joint replacement planning instead.

The third criterion is patient goals. Injection therapy is most appropriate when the aim is to delay or avoid surgery, not as a substitute for replacement in someone whose disease stage and preferences already point clearly towards it.

There is no validated scoring algorithm that defines the exact moment to escalate from physiotherapy to injection. The threshold is a clinical judgement, reached through specialist assessment that weighs symptom burden, imaging findings, and individual goals in combination.

Injectable options and what the evidence shows

Three main injectable agents are used in patellofemoral OA practice, each with a different mechanism and a different evidence footprint.

Hyaluronic acid (HA / viscosupplementation) has the broadest evidence base of the three. A 2015 network meta-analysis by Bannuru et al., published in the Annals of Internal Medicine, and a 2017 systematic review in BMC Musculoskeletal Disorders both confirm efficacy for mild-to-moderate knee OA. The practical caveat is that most trials enrolled mixed-compartment knee OA populations rather than patients with isolated PFOA; compartment-specific outcome data remain sparse. HA is generally well tolerated and can be repeated, making it a reasonable first injectable option for many patients.

Platelet-rich plasma (PRP) is increasingly used within broader knee OA practice, including PFOA. Evidence is accumulating, but heterogeneity in preparation protocols — platelet concentration, leucocyte content, number of injections — means that direct comparison across studies is limited. It is typically offered to patients who have not responded adequately to HA or who prefer a biologically active agent.

Polyacrylamide hydrogel (iPAAG / Arthrosamid®) carries patellofemoral-specific evidence that the other agents currently lack. A 2022 case series published in the Journal of Arthritis (Maulana and colleagues) documented a reduction in patellofemoral bone marrow lesions following a single iPAAG injection — a finding directly relevant to the PFOA population. Separately, Bliddal et al. demonstrated sustained benefit at 6 months (J Orthop Res Ther, 2021) and 12 months (J Orthop Surg Res, 2024) in knee OA, supporting its use as a long-acting cushioning agent for patients seeking to delay surgical intervention.

Corticosteroid injection may offer short-term pain relief in PFOA, but dedicated evidence for this compartment is limited; it is generally not regarded as a primary long-term strategy.

Across all four agents, head-to-head RCT data comparing them specifically in isolated PFOA — rather than mixed-compartment knee OA — remain sparse. This is a genuine evidence gap, not a reason to avoid injection therapy, but it does mean that individual clinical assessment and patient preference carry particular weight in agent selection.

Patient selection, expectations, and getting assessed

Injection therapy for patellofemoral OA is appropriate within a specific window in the disease course — not at the earliest signs, and not at bone-on-bone end-stage, but in the mild-to-moderate middle ground where cartilage is still present and symptoms have outrun what rehabilitation alone can address. Imaging-confirmed sub-total wear, treatment-resistant symptoms, and a goal of delaying or avoiding surgery are the three converging factors that typically define candidacy.

What to expect

Injection therapy reduces pain and supports function — it is not a cure, and setting realistic expectations before committing to treatment matters. Duration of benefit varies by agent and individual. Hyaluronic acid is commonly re-administered at intervals of months; duration data differ considerably across product formulations and disease stages, and the evidence does not support a single reliable figure. For polyacrylamide hydrogel (Arthrosamid®), knee OA data from Bliddal et al. suggest average symptom relief of approximately two to three years from a single injection, with repeat treatment available for suitable patients. PRP duration is harder to summarise owing to variability in preparation protocols across published studies; this is an active area of research rather than a settled data point.

The longer surgical picture is worth raising at any specialist assessment: patellofemoral arthroplasty and total knee replacement carry different indications depending on whether disease is compartment-specific or involves the tibiofemoral joint, and understanding where injection therapy sits in that broader sequence supports more informed planning.

Getting assessed

Confirming the compartmental diagnosis, reviewing up-to-date imaging, and judging whether injection therapy is the right next step all require specialist musculoskeletal input — GP-level review is not sufficient at this stage. The AMSK platform provides an assessment pathway for patients exploring injection options; the initial assessment form is at amsk.co.uk.

1. [1] Patellofemoral Pain Syndrome – Wikipedia. https://en.wikipedia.org/?curid=12033023 https://en.wikipedia.org/?curid=12033023
2. [2] Radiographic classification of osteoarthritis – Wikipedia. https://en.wikipedia.org/?curid=44226936 https://en.wikipedia.org/?curid=44226936